{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:15:09Z","timestamp":1790014509170,"version":"4.0.1"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The trajectories of core Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers and the concurrent cognitive changes across the clinical spectrum remain unclear yet are important for clinical trial design.<\/jats:p><\/jats:sec>Objective<\/jats:title>To map longitudinal CSF amyloid, tau, and cognitive trajectories along the clinical spectrum of AD and amyloid-negative controls.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This longitudinal cohort study included participants with a minimum of 2 CSF samples from Alzheimer Centrum Amsterdam cohorts across the AD clinical spectrum (ie, abnormal amyloid levels at first visit, in different clinical stages) and cognitively normal controls with initially normal CSF markers from November 2003 to July 2019. The maximum follow-up period was 19.5 years (median [IQR], 2 [0-3] years). Data were analyzed from March 2024 to May 2025.<\/jats:p><\/jats:sec>Exposures<\/jats:title>AD biomarkers (\u00df-amyloid [A\u00df]1-42 to A\u00df1-40 ratio, total tau [t-tau], and phosphorylated tau [p-tau]) detected in serially collected CSF.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>CSF AD biomarkers were measured with Lumipulse G600II. Cognition was measured using the Mini-Mental State Examination (MMSE) and delayed memory recall component of the of the Rey Auditory Verbal Learning Test. Analysis was conducted using linear mixed models, including random intercepts and slopes, adjusting for age, education level, and sex. Each model included an interaction term of time and clinical stage to study stage-specific slopes. Biomarker conversion rates per clinical stage were studied by comparing biomarker status between visits.<\/jats:p><\/jats:sec>Results<\/jats:title>The sample included 197 individuals (103 male [52.3%]), including 83 controls (mean [SD] age, 63 [8] years), 31 individuals with amyloid positivity who were cognitively unimpaired (mean [SD] age, 67 [9] years), 30 individuals with amyloid-positive mild cognitive impairment (MCI; mean [SD] age, 67 [7] years), and 53 individuals with amyloid-positive dementia (mean [SD] age, 65 [8] years). A\u03b21-42\/1-40 ratios decreased in controls (\u03b2 [SE]\u2009=\u2009\u22128.55\u2009\u00d7\u200910\u22124<\/jats:sup> [1.87\u2009\u00d7\u200910\u22124<\/jats:sup>]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and the amyloid-positive cognitively unimpaired group (\u03b2 [SE]\u2009=\u2009\u22121.05\u2009\u00d7\u200910\u22123<\/jats:sup> [3.14\u2009\u00d7\u200910\u22124<\/jats:sup>]; P<\/jats:italic>\u2009&amp;lt;\u2009.001), and remained low in amyloid-positive MCI and dementia groups. There were 10 controls (12.0%) who reached abnormal amyloid over a mean (SD) of 4.8 (3.4) years. In controls, CSF t-tau (\u03b2 [SE]\u2009=\u20098.49 [2.55] pg\/mL per year; P<\/jats:italic>\u2009=\u2009.002) and p-tau (\u03b2 [SE]\u2009=\u20091.36 [0.41] pg\/mL per year; P<\/jats:italic>\u2009=\u2009.001) levels increased over time, and levels also increased for those in the amyloid-positive cognitively unimpaired (t-tau: \u03b2 [SE]\u2009=\u200917.24 [4.58] pg\/mL per year; P<\/jats:italic>\u2009&amp;lt;\u2009.001; p-tau: \u03b2 [SE]\u2009=\u20093.10 [0.72] pg\/mL per year; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and amyloid-positive MCI (t-tau: \u03b2 [SE]\u2009=\u200930.80 [5.99] pg\/mL per year; P<\/jats:italic>\u2009&amp;lt;\u2009.001; p-tau: \u03b2 [SE]\u2009=\u20094.40 [0.93] pg\/mL per year; P<\/jats:italic>\u2009&amp;lt;\u2009.001) groups, with t-tau increasing further in the dementia group (\u03b2 [SE]\u2009=\u200924.97 [7.80] pg\/mL per year; P<\/jats:italic>\u2009=\u2009.002). Longitudinal increases in p-tau and t-tau were steeper in the amyloid-positive cognitively unimpaired and MCI groups than in controls, with 10 controls (12.0%) reaching abnormal p-tau and 12 controls (14.5%) reaching abnormal t-tau levels. Delayed recall declined most in the amyloid-positive cognitively unimpaired group (\u03b2 [SE]\u2009=\u2009\u22120.31 [0.07]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and was associated with CSF amyloid levels (\u03b2 [SE]\u2009=\u2009102.29 [47.30]; P<\/jats:italic>\u2009=\u2009.03). MMSE scores declined most in individuals with amyloid-positive MCI (\u03b2 [SE]\u2009=\u2009\u22121.25 [0.12]; P\u2009&amp;lt;\u2009.001) and dementia (\u03b2 [SE]\u2009=\u2009\u22121.89 [0.13]; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, CSF amyloid decreased toward abnormal levels in controls, declined further in the amyloid-positive cognitively unimpaired group , and was concurrent with decline of delayed recall; CSF amyloid stabilized in those with amyloid-positive MCI and dementia, while tau markers became increased (ie, more abnormal) in the amyloid-positive cognitively unimpaired and amyloid-positive MCI groups, suggesting that increase in CSF tau requires abnormal amyloid.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.19919","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:00:33Z","timestamp":1752159633000},"page":"e2519919","source":"Crossref","is-referenced-by-count":21,"title":["Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum"],"prefix":"10.1001","volume":"8","author":[{"given":"Diederick M.","family":"de Leeuw","sequence":"first","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Trieu","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"},{"name":"Department of Clinical Chemistry, Neurochemistry Lab and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Center, Location VUmc, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Vromen","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena R.","family":"Blujdea","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Neurochemistry Lab and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Center, Location VUmc, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Neurochemistry Lab and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Center, Location VUmc, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora H.","family":"Duits","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Neurochemistry Lab and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Center, Location VUmc, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"},{"name":"Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands"},{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty M.","family":"Tijms","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"zoi250618r1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-981-32-9358-8","article-title":"Amyloid-\u00df and tau at the crossroads of Alzheimer\u2019s disease.","volume":"1184","author":"Gallardo","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"zoi250618r2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade.","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"issue":"12","key":"zoi250618r3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct\u2014an international working group recommendation.","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"issue":"8","key":"zoi250618r4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup.","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"zoi250618r5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/archneurol.2009.316","article-title":"Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.","volume":"67","author":"Stomrud","year":"2010","journal-title":"Arch Neurol"},{"issue":"3","key":"zoi250618r6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209605","article-title":"Predicting cognitive decline in amyloid-positive patients with mild cognitive impairment or mild dementia.","volume":"103","author":"van der Veere","year":"2024","journal-title":"Neurology"},{"issue":"11","key":"zoi250618r7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acn3.51670","article-title":"Comparison of plasma and CSF biomarkers in predicting cognitive decline.","volume":"9","author":"Aschenbrenner","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"zoi250618r8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13195-024-01456-1","article-title":"Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer\u2019s disease: a systematic review.","volume":"16","author":"Oosthoek","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi250618r9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-020-00636-z","article-title":"The dynamics of biomarkers across the clinical spectrum of Alzheimer\u2019s disease.","volume":"12","author":"Hadjichrysanthou","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi250618r10","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12374","article-title":"Longitudinal CSF Alzheimer\u2019s disease biomarker changes from middle age to late adulthood.","volume":"14","author":"Pettigrew","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"zoi250618r11","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12095","article-title":"Clinical and biomarker trajectories in sporadic Alzheimer\u2019s disease: a longitudinal study.","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"issue":"Pt 9","key":"zoi250618r12","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1093\/brain\/awu176","article-title":"A data-driven model of biomarker changes in sporadic Alzheimer\u2019s disease.","volume":"137","author":"Young","year":"2014","journal-title":"Brain"},{"issue":"1","key":"zoi250618r13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JAD-230807","article-title":"Cerebrospinal fluid Alzheimer\u2019s disease biomarker patterns of change prior to the onset of mild cognitive impairment.","volume":"96","author":"Sun","year":"2023","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"zoi250618r14","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1093\/brain\/awy244","article-title":"Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.","volume":"141","author":"Roe","year":"2018","journal-title":"Brain"},{"issue":"8","key":"zoi250618r15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease.","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250618r16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jalz.2014.05.1754","article-title":"Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer\u2019s disease.","volume":"11","author":"Bertens","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"14","key":"zoi250618r17","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"zoi250618r18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","article-title":"Optimizing patient care and research: the Amsterdam dementia cohort.","volume":"41","author":"van der Flier","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"zoi250618r19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi250618r20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi250618r21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium.","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"zoi250618r22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants.","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"zoi250618r23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration.","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"zoi250618r24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria.","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"issue":"Pt 9","key":"zoi250618r25","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"3","key":"zoi250618r26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Pt 10","key":"zoi250618r27","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"},{"issue":"3","key":"zoi250618r28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome.","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"issue":"6","key":"zoi250618r29","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"zoi250618r30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop.","volume":"43","author":"Rom\u00e1n","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"zoi250618r31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","article-title":"Subjective cognitive impairment cohort (SCIENCe): study design and first results.","volume":"10","author":"Slot","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi250618r32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-018-0406-7","article-title":"The EMIF-AD PreclinAD study: study design and baseline cohort overview.","volume":"10","author":"Konijnenberg","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi250618r33","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12182","article-title":"Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.","volume":"13","author":"Willemse","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"zoi250618r34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.dadm.2015.09.002","article-title":"Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer\u2019s disease: a prospective 9-year study.","volume":"1","author":"Stomrud","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"zoi250618r35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","article-title":"Cerebrospinal fluid levels of \u00df-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.","volume":"69","author":"Buchhave","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"zoi250618r36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006294","article-title":"Longitudinal study of CSF biomarkers in patients with Alzheimer\u2019s disease.","volume":"4","author":"Buchhave","year":"2009","journal-title":"PLoS One"},{"issue":"12","key":"zoi250618r37","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease.","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"Pt 4","key":"zoi250618r38","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u00df accumulation earlier than positron emission tomography.","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"zoi250618r39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fneur.2015.00142","article-title":"Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD.","volume":"6","author":"Schindler","year":"2015","journal-title":"Front Neurol"},{"issue":"9","key":"zoi250618r40","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/acn3.615","article-title":"Pre-amyloid stage of Alzheimer\u2019s disease in cognitively normal individuals.","volume":"5","author":"Tijms","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"22","key":"zoi250618r41","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons.","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"zoi250618r42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum.","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi250618r43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/ana.26048","article-title":"Onset of preclinical Alzheimer disease in monozygotic twins.","volume":"89","author":"Konijnenberg","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"zoi250618r44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000051246","article-title":"Cerebrospinal fluid tau levels increase with age in healthy individuals.","volume":"12","author":"Blomberg","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"zoi250618r45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnagi.2017.00051","article-title":"Plasma tau levels in cognitively normal middle-aged and older adults.","volume":"9","author":"Chiu","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"zoi250618r46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1212\/WNL.0b013e3181e7ca82","article-title":"Serial MRI and CSF biomarkers in normal aging, MCI, and AD.","volume":"75","author":"Vemuri","year":"2010","journal-title":"Neurology"},{"issue":"16","key":"zoi250618r47","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1212\/WNL.0b013e3182a8418b","article-title":"Preclinical AD predicts decline in memory and executive functions in subjective complaints.","volume":"81","author":"van Harten","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"zoi250618r48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jalz.2012.08.004","article-title":"Cerebrospinal fluid A\u00df42 is the best predictor of clinical progression in patients with subjective complaints.","volume":"9","author":"van Harten","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"6","key":"zoi250618r49","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archneurol.2011.3354","article-title":"Amyloid-\u00df\u2013associated clinical decline occurs only in the presence of elevated P-tau.","volume":"69","author":"Desikan","year":"2012","journal-title":"Arch Neurol"},{"issue":"10","key":"zoi250618r50","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study.","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol"},{"issue":"5","key":"zoi250618r51","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","article-title":"Longitudinal change in CSF tau and A\u00df biomarkers for up to 48 months in ADNI.","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"7","key":"zoi250618r52","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","article-title":"Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease.","volume":"14","author":"Sutphen","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"12","key":"zoi250618r53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17126","article-title":"Association of longitudinal changes in cerebrospinal fluid total tau and phosphorylated tau 181 and brain atrophy with disease progression in patients with Alzheimer disease.","volume":"2","author":"Llibre-Guerra","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi250618r54","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal Fluid A\u00df42\/40 corresponds better than A\u00df42 to amyloid PET in Alzheimer\u2019s disease.","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"zoi250618r55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u00df42\/A\u00df40 and A\u00df42\/A\u00df38 ratios: better diagnostic markers of Alzheimer disease.","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"zoi250618r56","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12190","article-title":"P-tau\/A\u00df42 and A\u00df42\/40 ratios in CSF are equally predictive of amyloid PET status.","volume":"13","author":"Campbell","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"zoi250618r57","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/alz.12406","article-title":"Detection of Alzheimer\u2019s disease amyloid beta 1-42, p-tau, and t-tau assays.","volume":"18","author":"van Harten","year":"2022","journal-title":"Alzheimers Dement"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836241\/de_leeuw_2025_oi_250618_1751386387.99442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:00:34Z","timestamp":1752159634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.19919","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}